Nanomedicine: conservative approach and low funding keep EU trailing US
This article was originally published in Clinica
The EU is significantly behind the US when it comes to the number of companies that are active in the field of nanomedicine and the number of products currently available and in the pipeline.
You may also be interested in...
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.